How do I buy Black Diamond Therapeutic (BDTX) stock?

You can purchase shares of Black Diamond Therapeutic (NASDAQ:BDTX) through any online brokerage.View our list of the best stock brokerages

Who are Black Diamond Therapeutic (BDTX) competitors?

Other companies in Black Diamond Therapeutic’s space includes: Molecular Partners AG (NASDAQ:MOLN), Kalaris Therapeutics Inc (NASDAQ:KLRS), Innate Pharma SA (NASDAQ:IPHA), Elicio Therapeutics Inc (NASDAQ:ELTX) and Sangamo Therapeutics Inc (NASDAQ:SGMO).

What is the forecast, or price target, for Black Diamond Therapeutic (BDTX) stock?

Black Diamond Therapeutic has a consensus price target of $13.00.

What is the current price for Black Diamond Therapeutic (BDTX)?

The stock price for Black Diamond Therapeutic (NASDAQ: BDTX) is $2.8 last updated January 9, 2026 at 7:21 PM EST.

Does Black Diamond Therapeutic (BDTX) pay a dividend?

There are no upcoming dividends for Black Diamond Therapeutic.

When is Black Diamond Therapeutic (NASDAQ:BDTX) reporting earnings?

Black Diamond Therapeutic does not have any upcoming earnings scheduled.

Is Black Diamond Therapeutic (BDTX) going to split?

There is no upcoming split for Black Diamond Therapeutic.

What sector and industry does Black Diamond Therapeutic (BDTX) operate in?

Black Diamond Therapeutic is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Black Diamond Therapeutic (BDTX) Stock Price, Quote, News & History

Bulls vs Bears

Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Name

Revenue

Change

Gross

Change

EBITDA

Change

EBIT

Change

Earnings

Change

About

Sector

Health Care

Industry

Biotechnology

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic t...

Comments